ResultsIQ

ResultsIQ › Latest results › Kwality Pharmaceuticals Limited

Kwality Pharmaceuticals Limited Q2 FY27 results deck summary

NSE: KPL · BSE: 539997

Results deck of 12 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹181.2 cr and PAT ₹29.0 cr, with FY27 revenue guidance raised to ₹720+ cr from ₹700+ cr.

Key takeaways

  1. Q2 FY27 results Revenue was ₹181.2 cr (Q1 FY27: ₹162.4 cr) and PAT ₹29.0 cr at a 16.0% margin.
  2. FY27 guidance FY27 revenue guidance was raised to ₹720+ cr from ₹700+ cr, with EBITDA margin of 27-28%+.
  3. Margin expansion EBITDA margin rose to 27.5% in Q2 FY27 from 25.3% in Q1 FY27.
  4. Regulated markets EU-GMP certification from Hungary for Cephalosporin and Oncology plants and new LATAM, MENA and GCC registrations drive growth.
  5. Execution risk Unit 6 commercial production and license audit are still pending, with R&D of molecules 40% complete.

Original filing on BSE

Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.